Immunotherapy of peritoneal carcinomatosis.
Intraperitoneal immunotherapy actually is a promising concept for treatment of peritoneal carcinomatosis for several reasons: The use of specifically engineered therapy in terms of antibodies or stimulated T lymphocytes against epithelial tumour antigens offers an elegant way to attack tumours on the peritoneal surface, as peritoneal cells have a mesenchymal origin. This is especially true for modern multimodal treatment concepts, were local compartment treatment together with systemic chemotherapy and (if possible) surgical tumour removal will be individually combined.
Ströhlein
M A
MA
Department of Surgery, Merheim Medical Center, University of Witten/Herdecke, Koln-Merheim, Germany. StroehleinM@kliniken-koeln.de
Heiss
M M
MM
D000906:Antibodies / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000628:therapy*; D016207:Cytokines / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D010529:Peritoneal Cavity; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000628:therapy*; D010537:Peritoneum / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects
D000906:Antibodies; D016207:Cytokines